PF-04449913 Single-Agent In Patients with Myelofibrosis Previously Treated with a Janus Kinase Inhibitor

Overview

About this study

A lead-in cohort of PF-04449913 100mg daily dose will be evaluated in symptomatic primary or secondary myelofibrosis patients previously treated with 1 or more licensed or experimental Janus kinase inhibitors. Following the lead-in, a phase 2, randomized, double blind, 2 arm study of oral single agent PF 04449913 versus placebo will be tested in patients resistant or intolerant to ruxolitinib.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Diagnosis of primary or secondary myelofibrosis as per World Health Organization 2008 criteria.
  • Prior treatment with 1 or more JAK inhibitors (must meet one of the following criteria):
    1. Previous treatment with 1 or more JAK inhibitors (licensed or experimental) for a minimum duration of at least 4 weeks and failure to achieve or sustain adequate symptomatic control and/or achieve or sustain an adequate reduction of splenomegaly (Investigator's judgment);
    2. JAKi therapy discontinuation for unacceptable toxicity irrespective of the duration of therapy.
  • Spleen at least 5 cm below the inferior left costal margin as measured by manual palpation.
  • Symptomatic myelofibrosis
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2

Exclusion Criteria:

  • Previous treatment with a licensed or experimental smoothened inhibitor.
  • Other anti cancer therapy up to 14 days prior to enrollment, with the exception of hydroxyurea, which can be given up to 7 days prior to enrollment.
  • Splenic irradiation within 3 months prior to enrollment.
  • History of congenital long QT syndrome, or a baseline =>470 msec QTcF abnormality (average of the triplicate reading).

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Ruben Mesa, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

Jacksonville, Fla.

Mayo Clinic principal investigator

Ruben Mesa, M.D.

Closed for enrollment

Contact information:

Research Information Center

800-664-4542

More information

Publications

Publications are currently not available
.
CLS-20143570

Mayo Clinic Footer